Introduction
In the present work a special type of two-dimensional electrophoresis, combining blue native polyacrylamide gel electrophoresis (BN-PAGH) in the first dimension with Trieine%Sl)S-PAtiP. in the second dimension, was used. Major principles of BN-PAtJH are as follows: Membrane proteins are solubilized from biological mem branes by neutral detergents. Coomassie blue dye is added to the cathode buffer and to the protein solution before it is applied to an aerylamide gradient gel buff ered at pH 7. Negatively charged Coomassie dye binds to hydrophobic protein surfaces, keeps membrane proteins soluble in the detergent-free gel, drags proteins to the anode, and makes native proteins visible during the run. Protein migration stops when a limiting pore si/e of the gradient get is reached. Therefore, a separation of pro teins according to their molecular masses is achieved. Trieine-SDS-PAGP, used in the second dimension, then resolves the subunits of protein complexes. This two-dimensional (2-D) technique has been used for the quantification of oxidative phosphorylation (OXPHOS) complexes in Parkinson's disease [1] , in mitochondrial encephalomyopathies (2j, and for the detection of specific complex V deficiencies in A l/heim er's disease (3|. All these studies used tissue specimens from biopsies (skeletal muscle) and autopsies (brain, liver, heart) . Any technique that allows the use of patient cell lines, skin fibroblasts and lymphoblasts, or the use of the platelet fraction from blood would be of great benefit lor patients and researchers because less muscle biopsies would be required, and sufficient sample would be available for the analysis of the molec-ular basis of the defect. The enzymatic analysis of OXPHOS enzymes in fibroblast cell lines and in plate lets from patients with encephalomyopathy, Parkinson's or Alzheimer's disease, showed already that OXPHOS defects are also often detectable in fibroblasts [4, 5] and platelets [6, 7] , Direct application of the electrophoretic technique devel oped for skeletal muscle to cultured celts or blood plate lets is problematic because these cells have an approxi mately tenfold lower mitochondrial content compared to skeletal muscle. This would lead to overloading of gels and smearing of protein bands. On the other hand, a pre ceding preparation of mitochondria from cells is also problematic beeausc the yields of mitochondria obtained by conventional homogenization-ecntrifugation proce dures can vary considerably* Variations in protein quanti ties would then lead to variations in detergent/protein ratios used for membrane protein extraction, and to con siderable variations in the performance of 2-D gels. The major problem to be solved therefore was the develop ment of a protocol for the preparation of mitochondria from cells with reproducible yield.
Materials and Methods

Cell lines
Murine L-929 fibroblasts, human FL amnion cells, HeLa cervix carcinoma epithelial cells and primary fibroblasts from healthy individuals and from one patient with cytochrome oxidase deficiency were grown in Eagle's minimal essential medium in the presence of fetal calf serum and penicillin/streptomycin. Murine N IH /3T3 fibroblasts and human MoIt-4 T-cell lymphoblasts were grown in RPMI 1640 medium with fetal calf serum and penicillin/streptomycin. 
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:#í fy- Figure 3 shows the protein patterns in 2-D gels from Molt-4 lymphoblasts. The patterns from human cell lines, such as FL amnion cells and HeLa cells, look very similar (not shown). Complex I could rarely be identified in silver-stained 2-D gels from human cells, although it could be easily identified in murine cells (not shown).
Complex II comprises four different protein subunits in mammals with molecular masses of 70, 27, 13 and 9.0 kDa, although five protein bands can be detected, as indicated by the arrows (Fig. 3) . Amino-terminal protein sequencing revealed that the additional 9.3 kDa 'com ponent is the preprotein to the 9.0 kDa protein that is not yet processed to the mature 9.0 kDa form (ScMgger, Hm unpublished). Complex IV is present in two forms, the major monomeric form with the normal apparent molecular masses of 200 kDa and a minor IV'-form with an apparent mass of about 150 kDa. Several protein sub units, e.g. the 9.5 kDa subunit Via and the 7.0 kDa sub unit, are missing in the IV'-form. This can be caused by dissociation from the holo-complex at the high deter gent/protein ratio required for solubilization. Complex V-monomer and complex Ill-dim er with apparent molec ular masses of 600 kDa and 500 kDa in the first-dimen sional BN-PAGE (not shown) seem to be less sensitive to high detergent, and only one form each with the normal polypeptide composition [1-3] is observed in the second-dimensional SDS-PAGE.
Deviations from normal OXPHOS protein patterns in fibroblasts
A normal OXPHOS protein pattern from primary skin fibroblasts of a healthy individual is shown in Fig. 4A . Complex I again is the only complex that is usually not detected in Coomassie and silver-stained 2-D gels. A 2-D gel of a patient with mitochondrial encephalomyopathy is shown in Fig. 4B . Complex IV was hardly detectable in the patient's fibroblasts. This is in agreement with the low complex IV catalytic acitivity, measured in fibro blasts and muscle of the patient. The most prominent alteration, however, concerned complex V. The largest subunits of complex V, the alpha and beta subunits, were detected at two different locations, at the normal position of complex V, also called FjF0 ATP-synthase (600 kDa), and at the position of the free Fj subcomplex (400 kDa). Since BN-PAGE separates proteins according to their molecular masses [21] the Fx subcomplex will be found in the vicinity of complex III, which has an apparent molecular mass of 480 kDa [22] . This complex V abnormality, characterized by the presence of a consi derable portion of an Fj sub comp lex was detected nei ther in skeletal muscle samples nor in fibroblasts from control individuals. It was also absent in muscle samples from patients with deletions or individual defects of either complex I or complex IV [2]. However, it was found recently in muscle o f patients with Leigh's disease with normal complex IV, and a point m utation (T -+G at position 8933) in the m itochondrial ATP 6 gene [23] . The single amino acid exchange in a protein subunit of com plex V seemed to selectively influence the structural sta bility or assembly of this complex. In the present case a point m utation in any gene of a complex V subunit is unlikely, since additionally the am ount of assembled complex IV was reduced by 80%. We therefore suspect that a novel point m utation in either one of the m ito chondrial tRNAs could be responsible for the simulta neous expression of the complex V abnormality and the complex IV deficiency,
Concluding remarks
OXPHOS deficiencies present in skeletal muscle can also be expressed in skin fibroblasts in som e forms of mitochondrial encephalomyopathies [24] . If OXPHOS deficiencies are not detectable in fibroblasts of patients with mitochondrial encephalomyopathy, a needle or sur gical biopsy of skeletal m uscle will still be required* The possibility to use cell lines from control individuals and from patients offers the chance for studies of OXPHOS complexes under varying conditions, i.e., there is more flexibility in probing the influence of inhibitors, hor mones, and transcription factors. It seems possible to study the biogenesis, assembly, and turnover of OXPHOS complexes in cell cultures, and the influence of thyroid hormones, steriod horm ones, and cytokines on the OXPHOS system.
OXPHOS analysis in blood of patients certainly may have the same or even stronger restrictions as the anal ysis of cell lines. The percentage of the MELAS point mutation in mitochondrial DNA, for example, was found to be 90% in muscle, b u t only 25% in blood [5] . Sim ilarly, the chronic progressive external ophthalmoplegia (CPEO) and Kears Sayre syndrom e (KSS) forms of m ito chondrial encephalomyopathies are characterized by deletions in muscle m itochondrial DNA, but these dele tions are hardly detectable in blood cells. Therefore, the 2-D electrophoretic approach will n o t detect OXPHOS alterations in these cases (c f references in [25] ). In Pearson marrow-pancreas syndrom e, however, the gene ralized cytopenia correlates with a high percentage of mtDNA deletions in peripheral blood [26] , and enzy matic analyses revealed a complex IV deficiency in fibro blasts and lymphoblastoid cell lines [27] . Future experi ments will show if these genetic and enzymatic defects are also expressed by reduced am ounts o f assembled complexes or by altered ratios o f complexes in platelets. We would like to stress the potential use of the 2-D elec trophoretic technique for the analysis of G lanzm ann's thrombasthenia [13] or other diseases with defects in the platelet glycoprotein complex, e.g. neonatal alio immune thrombocytopenia [12] .
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